Aim: To investigate the associations between serum interleukin (IL) 18 concentrations and indices of lipid and carbohydrate metabolism in healthy adults. Methods: Fasting serum concentrations of IL-18, glucose, total cholesterol, triglyceride, and high- and low-density lipoprotein cholesterols were measured in 570 apparently healthy adults. Results: Univariate linear and partial regression analyses showed that the serum IL-18 concentration was positively correlated with serum triglyceride and glucose concentrations in both obese and diabetic subjects after controlling for the confounding effects of age, sex, and body mass index. Conclusion: IL-18 may be associated with obesity and glucose intolerance.

Keywords:
Carbohydrate, Glucose, Interleukin 18, Lipids
1.
Okamura H, Nagata K, Komatsu T, et al: A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 1995;63:3966–3972.
2.
Okamura H, Tsutsui H, Komatsu T, et al: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995;378:88–91.
3.
Ushio S, Namba M, Okura T, et al: Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996;156:4274–2479.
4.
Kohno K, Kataoka J, Ohtsuki T, et al: IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997;158:1541–1550.
5.
Micallef MJ, Ohtsuki T, Kohno K, et al: Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 1996;26:1647–1651.
6.
Tsutsui H, Nakanishi K, Matsui K, et al: IFN-γ-inducing factor upregulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996;157:3967–3973.
7.
Tsutsui H, Matsui K, Kawada N, et al: IL-18 accounts for both TNF-γ and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 1997;159:3961–3967.
8.
Puren AJ, Fantuzzi G, Gu Y, et al: Interleukin-18 (INF-γ-inducing factor) induces IL-8 and IL-1β via TNF-α production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998;101:711–721.
9.
Stoll S, Jonuleit H, Schmitt, et al: Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 1998;28:3231–3239.
10.
Stoll S, Müller G, Kurimoto M, et al: Production of IL-18 (IFN-γ-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol 1997;159:298–302.
11.
Takeuchi M, Nishizaki Y, Sano O, et al: Immunohistochemical and immuno-electron-microscopic detection of interferon-γ-inducing factor (‘interleukin-18’) in mouse intestinal epithelial cells. Cell Tissue Res 1997;289:499–503.
12.
Cameron LA, Taha RA, Tsicopoulos A, et al: Airway epithelium expresses interleukin-18. Eur Respir J 1999;14:553–559.
13.
Udagawa N, Horwood NJ, Elliott J, et al: Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J Exp Med 1997;185:1005–1012.
14.
Conti B, Park LC, Calingasa NY, et al: Cultures of astrocytes and microglia express interleukin-18. Brain Res Mol Brain Res 1999;67:46–52.
15.
Conti B, Jahng JW, Tinti C, et al: Induction of interferon-γ inducing factor in the adrenal cortex. J Biol Chem 1997;272:2035–2037.
16.
Olusi SO, Abiaka C, Abraham M, et al: Relationship among serum IL-18, TNF-γ, plasma malondialdehyde and body mass index in a healthy adult population (in press).
17.
Shoeler DA: Use of the body mass index (BMI) as a measure of overweight in children and adolescents. J Pediatr 1998;132:191–193.
18.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
19.
Kern PA, Saghizadeh M, Ong JM, et al: The expression of tumour necrosis factor in human adipose tissue: Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111–2119.
20.
Das UN: Is obesity an inflammatory condition? Nutrition 2001;17:953–966.
21.
Hill JO: A new way of looking at obesity. Nutrition 2001;17:975–976.
22.
Caro JE, Sinha MK, Kolaczynski JW, et al: Leptin: The role of an obesity gene. Diabetes 1996;45:1455–1462.
23.
Matson CA, Wister MF, Weigle DS: Leptin and the regulation of body adiposity. Diabetes Rev 1996;4:488–506.
24.
Stephens TW, Basinski M, Bristow PK, et al: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995;377:530–532.
25.
Vaisse C, Halaas JL, Horvath CM, et al: Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 1996;14:95–97.
26.
Levin BE, Routh VH: Role of the brain in energy balance and obesity. Am J Physiol 1996;271:R491–R500.
27.
Zhang Y, Proenca R, Maffei M, et al: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–432.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.